AU656353B2
(en)
*
|
1990-11-29 |
1995-02-02 |
Institut National De La Recherche Agronomique (Inra) |
New variants derived from interferons of type I, production process thereof and their applications
|
FR2669931B1
(fr)
*
|
1990-11-29 |
1995-03-31 |
Transgene |
Nouveaux variants derives des interferons-alpha et leur procede de production.
|
GB9127250D0
(en)
*
|
1991-12-23 |
1992-02-19 |
Unilever Plc |
Modification
|
FR2700338B1
(fr)
*
|
1993-01-11 |
1995-03-31 |
Transgene Sa |
Nouvelle séquence pro permettant la secrétion de protéines hétérologues à partir d'une cellule de levure.
|
FR2714908A1
(fr)
*
|
1994-01-11 |
1995-07-13 |
Transgene Sa |
Famille de peptides appelés xénoxines.
|
PT706567E
(pt)
*
|
1993-06-29 |
2001-10-31 |
Transgene Sa |
Familia de peptidos designados xenoxinas
|
US5712114A
(en)
*
|
1995-06-06 |
1998-01-27 |
Basf Aktiengesellschaft |
Compositions for expression of proteins in host cells using a preprocollagen signal sequence
|
US5837247A
(en)
*
|
1995-06-16 |
1998-11-17 |
United States Of America As Represented By The Public Health Service National Institutes Of Health |
Chemotactic agents for t-cells
|
US6998116B1
(en)
|
1996-01-09 |
2006-02-14 |
Genentech, Inc. |
Apo-2 ligand
|
US6030945A
(en)
*
|
1996-01-09 |
2000-02-29 |
Genentech, Inc. |
Apo-2 ligand
|
EP0904366A1
(en)
|
1996-04-01 |
1999-03-31 |
Genentech, Inc. |
Apo-2li and apo-3 apoptosis polypeptides
|
US6159462A
(en)
*
|
1996-08-16 |
2000-12-12 |
Genentech, Inc. |
Uses of Wnt polypeptides
|
US5851984A
(en)
*
|
1996-08-16 |
1998-12-22 |
Genentech, Inc. |
Method of enhancing proliferation or differentiation of hematopoietic stem cells using Wnt polypeptides
|
US6462176B1
(en)
|
1996-09-23 |
2002-10-08 |
Genentech, Inc. |
Apo-3 polypeptide
|
US6197545B1
(en)
|
1996-09-25 |
2001-03-06 |
Vanderbilt University |
Genetically engineered yeast with modified signal peptidase complex
|
US6342369B1
(en)
|
1997-05-15 |
2002-01-29 |
Genentech, Inc. |
Apo-2-receptor
|
WO1998055615A1
(en)
|
1997-06-05 |
1998-12-10 |
The University Of Texas Board Or Regents |
Apaf-1, the ced-4 human homolog, an activator of caspase-3
|
IL133122A0
(en)
|
1997-06-18 |
2001-03-19 |
Genentech Inc |
Apo-2dcr polypeptides
|
US6342220B1
(en)
|
1997-08-25 |
2002-01-29 |
Genentech, Inc. |
Agonist antibodies
|
DK1015587T3
(da)
|
1997-09-18 |
2008-08-25 |
Genentech Inc |
DcR3 polypeptid, en TNFR-homolog
|
IL135051A0
(en)
|
1997-10-10 |
2001-05-20 |
Genentech Inc |
Apo-3 ligand polypeptide
|
AU1126099A
(en)
|
1997-10-29 |
1999-05-17 |
Genentech Inc. |
Polypeptides and nucleic acids encoding the same
|
JP2003533164A
(ja)
|
1997-10-29 |
2003-11-11 |
ジェネンテック・インコーポレーテッド |
Wnt−1誘導分泌ポリペプチド:WISP−1,−2及び−3
|
JP3497133B2
(ja)
|
1997-11-21 |
2004-02-16 |
ジェネンテック・インコーポレーテッド |
A−33関連抗原およびそれらの薬理学的使用
|
US7192589B2
(en)
|
1998-09-16 |
2007-03-20 |
Genentech, Inc. |
Treatment of inflammatory disorders with STIgMA immunoadhesins
|
DE69939732D1
(de)
|
1998-01-15 |
2008-11-27 |
Genentech Inc |
Apo-2 ligand
|
US6727079B1
(en)
|
1998-02-25 |
2004-04-27 |
The United States Of America As Represented By The Department Of Health And Human Services |
cDNA encoding a gene BOG (B5T Over-expressed Gene) and its protein product
|
NZ525914A
(en)
|
1998-03-10 |
2004-03-26 |
Genentech Inc |
Novel polypeptides and nucleic acids encoding the same
|
EP1064382B1
(en)
|
1998-03-17 |
2008-08-20 |
Genentech, Inc. |
Polypeptides homologous to vegf and bmp1
|
EP1865061A3
(en)
|
1998-05-15 |
2007-12-19 |
Genentech, Inc. |
IL-17 homologous polypeptides and therapeutic uses thereof
|
EP3112468A1
(en)
|
1998-05-15 |
2017-01-04 |
Genentech, Inc. |
Il-17 homologous polypeptides and therapeutic uses thereof
|
IL138930A0
(en)
|
1998-05-15 |
2001-11-25 |
Genentech Inc |
Il-17 homologies polypeptides and therapeutic uses thereof
|
US6545140B1
(en)
*
|
1998-07-13 |
2003-04-08 |
University Of Georgia Research Foundation, Inc. |
DNA encoding an avian beta-defensin and uses thereof
|
US20020172678A1
(en)
|
2000-06-23 |
2002-11-21 |
Napoleone Ferrara |
EG-VEGF nucleic acids and polypeptides and methods of use
|
US7173115B2
(en)
|
2000-01-13 |
2007-02-06 |
Genentech, Inc. |
Stra6 polypeptides
|
SI1135498T1
(sl)
|
1998-11-18 |
2008-06-30 |
Genentech Inc |
Variante protitelesa z višjo vezavno afiniteto vprimerjavi z izvirnimi protitelesi
|
EP1820859B9
(en)
|
1998-12-22 |
2009-10-28 |
Genentech, Inc. |
Methods and compositions for inhibiting neoplastic cell growth
|
EP2330198A1
(en)
|
1998-12-23 |
2011-06-08 |
Genentech, Inc. |
IL-1 related polypeptides
|
ES2694002T3
(es)
|
1999-01-15 |
2018-12-17 |
Genentech, Inc. |
Polipéptido que comprende una región Fc de IgG1 humana variante
|
DE60043322D1
(de)
|
1999-06-15 |
2009-12-24 |
Genentech Inc |
Sekretierte und Transmembran-Polypeptide sowie Nukleinsäuren zu deren Kodierung
|
CN101121750A
(zh)
|
1999-06-25 |
2008-02-13 |
杰南技术公司 |
人源化抗ErbB2抗体及用抗ErbB2抗体进行的治疗
|
BR0015055A
(pt)
|
1999-10-20 |
2002-07-16 |
Genentech Inc |
Método de aumento estimulação ou potencialização da diferenciação de células t, método de tratamento de uma doença mediada por th1 em um mamìfero, método de prevenir, inibir ou atenuar a diferenciação de céluas t, método de tratamento de uma doença mediada por th2, em um mamìfero, método de determinação da presença de polipeptìdeo tccr em uma célula, método de diagnóstico de doenças mediadas por th1 ou mediadas por th2 em um mamìfero, método de identificação de compostos capazes de inibir a expressão de polipeptìdeos tccr e método para identificação de compostos capazes de inibir a atividade biológica de polipeptìdeo tccr, uso de antagonistas e agonistas de polipeptìdeos tccr
|
CA2491433A1
(en)
|
1999-12-01 |
2001-06-07 |
Genentech, Inc. |
Secreted and transmembrane polypeptides and nucleic acids encoding the same
|
EP1897943B1
(en)
|
1999-12-23 |
2011-12-14 |
Genentech, Inc. |
IL-17 homologous polypeptides and therapeutic uses thereof
|
AU7476600A
(en)
|
1999-12-30 |
2001-07-16 |
Genencor International, Inc. |
Trichoderma reesei xylanase
|
DE60133884D1
(de)
|
2000-03-24 |
2008-06-19 |
Genencor Int |
Herstellung von sekretierten proteinen durch rekombinante eukaryotische zellen
|
PT2857516T
(pt)
|
2000-04-11 |
2017-08-28 |
Genentech Inc |
Anticorpos multivalentes e utilizações dos mesmos
|
EP2077276A1
(en)
|
2000-06-23 |
2009-07-08 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of disorders involving angiogensis
|
EP2042597B1
(en)
|
2000-06-23 |
2014-05-07 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
|
IL153948A0
(en)
|
2000-07-27 |
2003-07-31 |
Genentech Inc |
Apo-2l receptor agonist and cpt-11 synergism
|
EP2014298A3
(en)
|
2000-08-24 |
2009-10-07 |
Genentech, Inc. |
Interleukin-22 polypeptides, nucleic acids encoding the same and methods for the treatment of pancreatic disorders
|
EP1944317A3
(en)
|
2000-09-01 |
2008-09-17 |
Genentech, Inc. |
Secreted and transmembrane polypeptides and nucleic acids encoding the same
|
US6673580B2
(en)
|
2000-10-27 |
2004-01-06 |
Genentech, Inc. |
Identification and modification of immunodominant epitopes in polypeptides
|
US20070160576A1
(en)
|
2001-06-05 |
2007-07-12 |
Genentech, Inc. |
IL-17A/F heterologous polypeptides and therapeutic uses thereof
|
MXPA03011985A
(es)
|
2001-06-20 |
2004-03-26 |
Genentech Inc |
Composiciones y metodos para el diagnostico y tratamiento de tumores.
|
NZ530985A
(en)
|
2001-08-29 |
2006-03-31 |
Genentech Inc |
Bv8 nucleic acids and polypeptides with mitogenic activity
|
ES2390531T3
(es)
|
2001-09-18 |
2012-11-13 |
Genentech, Inc. |
Composiciones y procedimientos para el diagnósitco y tratamiento de tumor
|
US20030228305A1
(en)
|
2002-01-02 |
2003-12-11 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
JP2005535290A
(ja)
|
2002-02-22 |
2005-11-24 |
ジェネンテック・インコーポレーテッド |
免疫関連疾患の治療のための組成物と方法
|
JP2005536190A
(ja)
|
2002-04-16 |
2005-12-02 |
ジェネンテック・インコーポレーテッド |
腫瘍の診断と治療のための組成物と方法
|
EP2305710A3
(en)
|
2002-06-03 |
2013-05-29 |
Genentech, Inc. |
Synthetic antibody phage libraries
|
KR20050004914A
(ko)
|
2002-06-07 |
2005-01-12 |
제넨테크, 인크. |
종양의 진단 및 치료 방법 및 이를 위한 조성물
|
EP2383278A1
(en)
|
2002-07-08 |
2011-11-02 |
Genentech, Inc. |
Method to determine B cell mediated diseases
|
PT2263691E
(pt)
|
2002-07-15 |
2012-11-12 |
Hoffmann La Roche |
Tratamento de cancro com o anticorpo anti-erbb2 monoclonal humanizado recombinante 2c4 (rhumab 2c4)
|
JP5401001B2
(ja)
|
2002-09-11 |
2014-01-29 |
ジェネンテック, インコーポレイテッド |
免疫関連疾患の治療のための新規組成物と方法
|
AU2003276874B2
(en)
|
2002-09-11 |
2009-09-03 |
Genentech, Inc. |
Novel compositions and methods for the treatment of immune related diseases
|
WO2004024097A2
(en)
|
2002-09-16 |
2004-03-25 |
Genentech, Inc. |
Compositions and methods for the treatment of immune related diseases
|
EP1585482A4
(en)
|
2002-09-25 |
2009-09-09 |
Genentech Inc |
NEW COMPOSITIONS AND METHODS FOR TREATING PSORIASIS
|
EP1576137A4
(en)
|
2002-10-29 |
2010-06-30 |
Genentech Inc |
COMPOSITIONS AND METHODS FOR TREATING DISEASES RELATED TO THE IMMUNE SYSTEM
|
EP1581169A4
(en)
|
2002-11-08 |
2008-09-17 |
Genentech Inc |
COMPOSITIONS AND METHODS FOR TREATING DISEASES RELATED TO NATURAL K CELLS
|
CA2504144A1
(en)
|
2002-11-26 |
2004-06-10 |
Genentech, Inc. |
Compositions and methods for the diagnosis of immune related diseases using pro7
|
WO2004070011A2
(en)
|
2003-02-01 |
2004-08-19 |
Tanox, Inc. |
HIGH AFFINITY ANTI-HUMAN IgE ANTIBODIES
|
JP4912144B2
(ja)
|
2003-03-12 |
2012-04-11 |
ジェネンテック, インコーポレイテッド |
造血促進のためのbv8及び/又はeg−vegfの使用
|
DK1610820T4
(da)
|
2003-04-04 |
2013-11-04 |
Genentech Inc |
Høj-koncentration antistof- og proteinformuleringer
|
ME00425B
(me)
|
2003-05-30 |
2011-10-10 |
Genentech Inc |
Liječenje sa anti-vegf antitijelima
|
WO2005000892A2
(en)
|
2003-06-12 |
2005-01-06 |
Eli Lilly And Company |
Glp-1 analog fusion plroteins
|
US7097993B2
(en)
|
2003-06-25 |
2006-08-29 |
Wisconsin Alumni Research Foundation |
Method for identifying an agent that modulates type 1 phosphatidylinositol phosphate kinase isoform β661 activity
|
PT2784084T
(pt)
|
2003-07-08 |
2019-10-01 |
Genentech Inc |
Anticorpos antagonistas contra polipéptidos heterólogos il-17a/f
|
US20050106667A1
(en)
|
2003-08-01 |
2005-05-19 |
Genentech, Inc |
Binding polypeptides with restricted diversity sequences
|
WO2005019258A2
(en)
|
2003-08-11 |
2005-03-03 |
Genentech, Inc. |
Compositions and methods for the treatment of immune related diseases
|
DE602004024921D1
(de)
|
2003-11-17 |
2010-02-11 |
Genentech Inc |
Zusammensetzungen und verfahren zur behandlung von tumoren hämatopoetischen ursprungs
|
WO2005060661A2
(en)
|
2003-12-19 |
2005-07-07 |
The Regents Of The University Of California |
Methods and materials for assessing prostate cancer therapies
|
BRPI0506726B8
(pt)
|
2004-01-07 |
2021-05-25 |
Chiron Corp |
anticorpo monoclonal específico para m-csf e usos deste
|
NZ550102A
(en)
|
2004-02-24 |
2010-10-29 |
Univ California |
Methods and materials for assessing prostate cancer therapies and compounds (thiohydantoine derivatives)
|
DK1730191T3
(da)
|
2004-03-30 |
2011-10-17 |
Glaxo Group Ltd |
Immunglobulin som binder HOSM
|
TWI307630B
(en)
|
2004-07-01 |
2009-03-21 |
Glaxo Group Ltd |
Immunoglobulins
|
WO2006014729A2
(en)
|
2004-07-20 |
2006-02-09 |
Genentech, Inc. |
Inhibitors of angiopoietin-like 4 protein, combinations, and their use
|
ATE462726T1
(de)
|
2005-01-07 |
2010-04-15 |
Diadexus Inc |
Ovr110-antikörperzusammensetzungen und verwendungsverfahren dafür
|
US7709517B2
(en)
|
2005-05-13 |
2010-05-04 |
The Regents Of The University Of California |
Diarylhydantoin compounds
|
EP1871163A2
(en)
|
2005-06-06 |
2008-01-02 |
Genentech, Inc. |
Transgenic models for different genes and their use for gene characterization
|
EP2311876A3
(en)
|
2005-07-28 |
2011-04-27 |
Novartis AG |
M-CSF-specific monoclonal antibody and uses thereof
|
ZA200800970B
(en)
|
2005-08-15 |
2009-10-28 |
Genentech Inc |
Gene disruptions, compositions and methods relating thereto
|
UA96139C2
(uk)
|
2005-11-08 |
2011-10-10 |
Дженентек, Інк. |
Антитіло до нейропіліну-1 (nrp1)
|
MY147669A
(en)
|
2005-11-18 |
2012-12-31 |
Glenmark Pharmaceuticals Sa |
Anti-alpha2 integrin antibodies and their uses
|
CA2630432A1
(en)
|
2005-11-21 |
2007-07-19 |
Genentech, Inc. |
Novel gene disruptions, compositions and methods relating thereto
|
EP1988768A2
(en)
|
2006-02-17 |
2008-11-12 |
Genentech, Inc. |
Gene disruptions, compositions and methods relating thereto
|
JP2009529915A
(ja)
|
2006-03-20 |
2009-08-27 |
ゾーマ テクノロジー リミテッド |
ガストリン物質に対して特異的なヒト抗体および方法
|
AU2007227224A1
(en)
|
2006-03-23 |
2007-09-27 |
Novartis Ag |
Anti-tumor cell antigen antibody therapeutics
|
DK2368550T3
(da)
|
2006-03-27 |
2013-09-30 |
Univ California |
Androgenreceptormodulator til behandlingen af prostatakræft og androgenreceptor-associerede sygdomme
|
SG170809A1
(en)
|
2006-03-29 |
2011-05-30 |
Univ California |
Diarylthiohydantoin compounds
|
AU2007243946B2
(en)
|
2006-04-05 |
2012-11-29 |
Curis, Inc. |
Method for using BOC/CDO to modulate hedgehog signaling
|
JP2009536022A
(ja)
|
2006-04-19 |
2009-10-08 |
ジェネンテック・インコーポレーテッド |
新規の遺伝子破壊、それに関連する組成物および方法
|
JP5829004B2
(ja)
|
2006-06-30 |
2015-12-09 |
ノボ・ノルデイスク・エー/エス |
抗nkg2a抗体とその使用
|
KR101437188B1
(ko)
|
2006-08-04 |
2014-10-02 |
노바르티스 아게 |
Ephb3-특이적 항체 및 이의 용도
|
DK2059535T3
(da)
|
2006-08-18 |
2014-01-13 |
Novartis Ag |
Prlr-specifikt antistof og anvendelser deraf
|
EP3284825B1
(en)
|
2006-11-02 |
2021-04-07 |
Biomolecular Holdings LLC |
Methods of producing hybrid polypeptides with moving parts
|
KR20090110295A
(ko)
|
2006-11-22 |
2009-10-21 |
에드넥서스, 어 브리스톨-마이어스 스퀴브 알&디 컴파니 |
Igf-ir을 포함하는 티로신 키나제 수용체에 대한 공학처리된 단백질에 기반한 표적화 치료제
|
CA2670696A1
(en)
|
2006-11-27 |
2008-06-05 |
Diadexus, Inc. |
Ovr110 antibody compositions and methods of use
|
ES2435437T3
(es)
|
2006-12-07 |
2013-12-19 |
Novartis Ag |
Anticuerpos antagonistas contra Ephb3
|
ATE516814T1
(de)
|
2007-02-02 |
2011-08-15 |
Bristol Myers Squibb Co |
10fn3 domain zur behandlung von krankheiten begleitet von unerwünschter angiogenese
|
AR065271A1
(es)
|
2007-02-09 |
2009-05-27 |
Genentech Inc |
Anticuerpos anti-robo4 y sus usos
|
KR101508397B1
(ko)
|
2007-02-22 |
2015-04-08 |
제넨테크, 인크. |
염증성 장 질환의 검출 방법
|
JP5683265B2
(ja)
|
2007-06-07 |
2015-03-11 |
ジェネンテック, インコーポレイテッド |
補体が関係している障害の予防および処置のためのc3b抗体ならびに方法
|
CL2008002085A1
(es)
|
2007-07-16 |
2008-11-21 |
Genentech Inc |
Anticuerpo humanizado anti-cd79b/igbeta/b29; polinucleotido codificacnte, vector, celula huesped; metodo de fabricacion; inmunoconjugado; composicion farmaceutica; uso para tratar cancer; metodo in vitro para determinar presencia de cd79b, oinhibir crecimiento de celulas quqe expresa cd79b; ensayo in vitro para detectar celulas b
|
NZ583318A
(en)
|
2007-07-16 |
2012-07-27 |
Genentech Inc |
Humanized anti-cd79b antibodies and immunoconjugates and methods of use
|
JP5535925B2
(ja)
|
2007-10-26 |
2014-07-02 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
アンドロゲン受容体調節物質としてのジアリールヒダントイン化合物
|
EP2209807A1
(en)
|
2007-11-08 |
2010-07-28 |
Genentech, Inc. |
Anti-factor b antibodies and their uses
|
CA2705555A1
(en)
|
2007-11-12 |
2009-05-22 |
Theraclone Sciences, Inc. |
Compositions and methods for the therapy and diagnosis of influenza
|
TWI580694B
(zh)
|
2007-11-30 |
2017-05-01 |
建南德克公司 |
抗-vegf抗體
|
AR070141A1
(es)
|
2008-01-23 |
2010-03-17 |
Glenmark Pharmaceuticals Sa |
Anticuerpos humanizados especificos para el factor von willebrand
|
EP2628753A1
(en)
|
2008-01-24 |
2013-08-21 |
Novo Nordisk A/S |
Humanized anti-human NKG2A monoclonal antibody
|
UA106586C2
(uk)
|
2008-01-31 |
2014-09-25 |
Дженентек, Інк. |
Анти-cd79b антитіла, і імунокон'югати та способи їх застосування
|
KR20100128291A
(ko)
|
2008-02-14 |
2010-12-07 |
브리스톨-마이어스 스큅 컴퍼니 |
Egfr에 결합하는 조작된 단백질을 기초로 하는 표적화된 치료제
|
MX2010009885A
(es)
|
2008-03-10 |
2010-11-30 |
Theraclone Sciences Inc |
Composiciones y métodos para la terapia y diagnóstico de citomegalovirus.
|
CA2905334A1
(en)
|
2008-04-09 |
2009-10-15 |
Genentech, Inc. |
Novel compositions and methods for the treatment of immune related diseases
|
CR20170001A
(es)
|
2008-04-28 |
2017-08-10 |
Genentech Inc |
Anticuerpos anti factor d humanizados
|
AR071874A1
(es)
|
2008-05-22 |
2010-07-21 |
Bristol Myers Squibb Co |
Proteinas de dominio de armazon basadas en fibronectina multivalentes
|
WO2010052556A1
(en)
|
2008-11-06 |
2010-05-14 |
Glenmark Pharmaceuticals S.A. |
Treatment with anti-alpha2 integrin antibodies
|
TWI496582B
(zh)
|
2008-11-24 |
2015-08-21 |
必治妥美雅史谷比公司 |
雙重專一性之egfr/igfir結合分子
|
SG172219A1
(en)
|
2008-12-17 |
2011-07-28 |
Genentech Inc |
Hepatitis c virus combination therapy
|
TW201029662A
(en)
|
2008-12-19 |
2010-08-16 |
Glaxo Group Ltd |
Novel antigen binding proteins
|
SI3260136T1
(sl)
|
2009-03-17 |
2021-05-31 |
Theraclone Sciences, Inc. |
Humani imunodeficientni virus (HIV)-nevtralizirajoča protitelesa
|
KR20120057565A
(ko)
|
2009-04-01 |
2012-06-05 |
제넨테크, 인크. |
항-FcRH5 항체 및 면역접합체 및 사용 방법
|
WO2010118243A2
(en)
|
2009-04-08 |
2010-10-14 |
Genentech, Inc. |
Use of il-27 antagonists to treat lupus
|
CA2759506A1
(en)
|
2009-04-23 |
2010-10-28 |
Theraclone Sciences, Inc. |
Granulocyte-macrophage colony-stimulating factor (gm-csf) neutralizing antibodies
|
US8858948B2
(en)
|
2009-05-20 |
2014-10-14 |
Theraclone Sciences, Inc. |
Compositions and methods for the therapy and diagnosis of influenza
|
AR077595A1
(es)
|
2009-07-27 |
2011-09-07 |
Genentech Inc |
Tratamientos de combinacion
|
AU2010289400B2
(en)
|
2009-09-02 |
2014-10-23 |
Curis, Inc. |
Mutant smoothened and methods of using the same
|
JP6016636B2
(ja)
|
2009-10-15 |
2016-10-26 |
ジェネンテック, インコーポレイテッド |
改変したレセプター特異性を持つキメラ線維芽細胞増殖因子
|
JP5819308B2
(ja)
|
2009-10-22 |
2015-11-24 |
ジェネンテック, インコーポレイテッド |
マクロファージ刺激タンパク質のヘプシン活性化を調節するための方法及び組成物
|
WO2011056497A1
(en)
|
2009-10-26 |
2011-05-12 |
Genentech, Inc. |
Activin receptor type iib compositions and methods of use
|
WO2011056502A1
(en)
|
2009-10-26 |
2011-05-12 |
Genentech, Inc. |
Bone morphogenetic protein receptor type ii compositions and methods of use
|
WO2011056494A1
(en)
|
2009-10-26 |
2011-05-12 |
Genentech, Inc. |
Activin receptor-like kinase-1 antagonist and vegfr3 antagonist combinations
|
TW201121570A
(en)
|
2009-11-12 |
2011-07-01 |
Genentech Inc |
A method of promoting dendritic spine density
|
CN103724432B
(zh)
|
2009-11-30 |
2016-06-08 |
霍夫曼-拉罗奇有限公司 |
治疗和诊断表达slc34a2(tat211=seqid2)的肿瘤的抗体
|
WO2011071577A1
(en)
|
2009-12-11 |
2011-06-16 |
Genentech, Inc. |
Anti-vegf-c antibodies and methods using same
|
WO2011080050A2
(en)
|
2009-12-11 |
2011-07-07 |
Novartis Ag |
Binding molecules
|
TW201636048A
(zh)
|
2009-12-21 |
2016-10-16 |
建南德克公司 |
抗體調配物
|
WO2011094259A2
(en)
|
2010-01-28 |
2011-08-04 |
Glaxo Group Limited |
Cd127 binding proteins
|
EP3124481B1
(en)
|
2010-02-16 |
2018-03-28 |
Aragon Pharmaceuticals, Inc. |
Androgen receptor modulators and uses thereof
|
EA201270713A1
(ru)
|
2010-02-18 |
2013-01-30 |
Бристол-Майерс Сквибб Компани |
Белки на основе фибронектина с каркасными доменами, которые связывают ил-23
|
WO2011104604A2
(en)
|
2010-02-23 |
2011-09-01 |
Glenmark Pharmaceuticals S.A. |
Anti-alpha2 integrin antibodies and their uses
|
EP2538981B1
(en)
|
2010-02-23 |
2017-12-20 |
F. Hoffmann-La Roche AG |
Compositions and methods for the diagnosis and treatment of tumor
|
UA108227C2
(xx)
|
2010-03-03 |
2015-04-10 |
|
Антигензв'язуючий білок
|
US8591900B2
(en)
|
2010-03-31 |
2013-11-26 |
Boehringer Ingelheim International Gmbh |
Anti-CD40 antibodies
|
KR20130056871A
(ko)
|
2010-04-13 |
2013-05-30 |
브리스톨-마이어스 스큅 컴퍼니 |
Pcsk9에 결합하는 피브로넥틴 기반 스캐폴드 도메인 단백질
|
WO2011133931A1
(en)
|
2010-04-22 |
2011-10-27 |
Genentech, Inc. |
Use of il-27 antagonists for treating inflammatory bowel disease
|
WO2011139985A1
(en)
|
2010-05-03 |
2011-11-10 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
TW201138808A
(en)
|
2010-05-03 |
2011-11-16 |
Bristol Myers Squibb Co |
Serum albumin binding molecules
|
BR112012029904A2
(pt)
|
2010-05-25 |
2017-08-08 |
Genentech Inc |
métodos de purificação de polipeptídeos
|
EP2576615B1
(en)
|
2010-05-26 |
2016-03-30 |
Bristol-Myers Squibb Company |
Fibronectin based scaffold proteins having improved stability
|
JP2013534515A
(ja)
|
2010-06-01 |
2013-09-05 |
モナシュ ユニバーシティ |
プロセシングされていない受容体型チロシンキナーゼc−METに対する抗体
|
UY33421A
(es)
|
2010-06-03 |
2011-12-30 |
Glaxo Wellcome House |
Proteinas de union al antígeno humanizados
|
CN103037887B
(zh)
|
2010-06-25 |
2017-11-10 |
国家医疗保健研究所 |
用于治疗呼吸道感染的方法和药物组合物
|
JP5883443B2
(ja)
|
2010-07-22 |
2016-03-15 |
グラクソスミスクライン バイオロジカルズ ソシエテ アノニム |
新規の抗原結合タンパク質
|
CA2807664A1
(en)
|
2010-08-12 |
2012-02-16 |
Theraclone Sciences, Inc. |
Anti-hemagglutinin antibody compositions and methods of use thereof
|
EP2603525A1
(en)
|
2010-08-13 |
2013-06-19 |
F.Hoffmann-La Roche Ag |
Antibodies to il-1beta and il-18, for treatment of disease
|
CA3201524A1
(en)
|
2010-08-31 |
2012-03-08 |
Theraclone Sciences, Inc. |
Human immunodeficiency virus (hiv)-neutralizing antibodies
|
WO2012036884A2
(en)
|
2010-09-15 |
2012-03-22 |
Aligna Technologies, Inc. |
Bioproduction of aromatic chemicals from lignin-derived compounds
|
WO2012047968A2
(en)
|
2010-10-05 |
2012-04-12 |
Genentech, Inc. |
Mutant smoothened and methods of using the same
|
US9347950B2
(en)
|
2010-10-08 |
2016-05-24 |
Shanghai Kexin Biotech Co., Ltd. |
Moesin fragments associated with immune thrombocytopenia
|
KR101708533B1
(ko)
|
2010-10-08 |
2017-02-20 |
상하이 켁신 바이오테크 씨오., 엘티디. |
재생불량 빈혈과 관련된 모에신 단편
|
EP2624851B1
(en)
|
2010-10-08 |
2016-11-30 |
Shanghai Kexin Biotech Co., Ltd |
Moesin fragments and uses thereof
|
US9345765B2
(en)
|
2010-10-08 |
2016-05-24 |
Shanghai Kexin Biotech Co., Ltd. |
Diagnostic and therapeutic uses of moesin fragments
|
EP2624854B1
(en)
|
2010-10-08 |
2016-08-03 |
Shanghai Kexin Biotech Co., Ltd |
Moesin inhibitors and uses thereof
|
EP3115375A1
(en)
|
2010-11-04 |
2017-01-11 |
Boehringer Ingelheim International GmbH |
Anti-il-23 antibodies
|
JP2014504587A
(ja)
|
2010-12-22 |
2014-02-24 |
ブリストル−マイヤーズ スクイブ カンパニー |
Il−23に結合するフィブロネクチンをベースとするスカフォールドドメインタンパク質
|
AU2011349049B2
(en)
|
2010-12-22 |
2016-08-11 |
Teva Pharmaceuticals Australia Pty Ltd |
Modified antibody with improved half-life
|
MX2013009357A
(es)
|
2011-02-14 |
2014-02-17 |
Theraclone Sciences Inc |
Composiciones y metodos para la terapia y diagnostico de la influenza.
|
EP2683735A1
(en)
|
2011-03-10 |
2014-01-15 |
HCO Antibody, Inc. |
Bispecific three-chain antibody-like molecules
|
WO2012122512A1
(en)
|
2011-03-10 |
2012-09-13 |
Hco Antibody, Inc. |
Recombinant production of mixtures of single chain antibodies
|
WO2012125614A1
(en)
|
2011-03-15 |
2012-09-20 |
Theraclone Sciences, Inc. |
Compositions and methods for the therapy and diagnosis of influenza
|
EP3415528B1
(en)
|
2011-04-13 |
2021-05-26 |
Bristol-Myers Squibb Company |
Fc fusion proteins comprising novel linkers or arrangements
|
CN103732623B
(zh)
|
2011-06-03 |
2017-09-29 |
佐马技术有限公司 |
对TGF‑β具有特异性的抗体
|
JP2013040160A
(ja)
|
2011-07-01 |
2013-02-28 |
Genentech Inc |
自己免疫疾患を治療するための抗cd83アゴニスト抗体の使用
|
WO2013033069A1
(en)
|
2011-08-30 |
2013-03-07 |
Theraclone Sciences, Inc. |
Human rhinovirus (hrv) antibodies
|
WO2013067029A2
(en)
|
2011-10-31 |
2013-05-10 |
Bristol-Myers Squibb Company |
Fibronectin binding domains with reduced immunogenicity
|
US20140315274A1
(en)
*
|
2011-11-11 |
2014-10-23 |
Novozymes A/S |
Methods For Production of Archeae Protease in Yeast
|
EP2780373B1
(en)
|
2011-11-16 |
2019-08-21 |
Boehringer Ingelheim International GmbH |
Anti il-36r antibodies
|
AU2012318288B2
(en)
|
2011-12-01 |
2015-09-17 |
Ap Biosciences, Inc. |
Protein inhibitors to complement and VEGF pathways and methods of use thereof
|
BR112014018471A2
(pt)
|
2012-01-31 |
2017-07-04 |
Genentech Inc |
anticorpos anti-ige m1' e métodos para o seu uso
|
US9605058B2
(en)
|
2012-05-01 |
2017-03-28 |
Glaxosmithkline Llc |
Antibodies against the CXC-ELR family of chemokines
|
AU2013256724A1
(en)
|
2012-05-03 |
2014-10-30 |
Boehringer Ingelheim International Gmbh |
Anti-IL-23p19 antibodies
|
BR112015005466B1
(pt)
|
2012-09-13 |
2023-04-11 |
Bristol-Myers Squibb Company |
Polipeptídeo e seu uso, composição farmacêutica e seu uso, molécula de ácido nucleico isolada, célula hospedeira, e método de detecção ou medição da miostatina em uma amostra
|
CN104661658A
(zh)
|
2012-09-26 |
2015-05-27 |
阿拉贡药品公司 |
用于治疗非转移性去势抵抗性***癌的抗雄激素
|
US10344099B2
(en)
|
2012-11-05 |
2019-07-09 |
Zenyaku Kogyo Kabushikikaisha |
Antibody and antibody composition production method
|
ES2614039T3
(es)
|
2012-12-07 |
2017-05-29 |
Danisco Us Inc. |
Composiciones y métodos de uso
|
US20150344923A1
(en)
*
|
2012-12-07 |
2015-12-03 |
Danisco Us Inc. |
Compositions and methods of use
|
BR112015012968A2
(pt)
|
2012-12-07 |
2017-09-12 |
Danisco Us Inc |
composições e métodos de uso
|
JOP20200097A1
(ar)
|
2013-01-15 |
2017-06-16 |
Aragon Pharmaceuticals Inc |
معدل مستقبل أندروجين واستخداماته
|
WO2014116749A1
(en)
|
2013-01-23 |
2014-07-31 |
Genentech, Inc. |
Anti-hcv antibodies and methods of using thereof
|
US20150361159A1
(en)
|
2013-02-01 |
2015-12-17 |
Bristol-Myers Squibb Company |
Fibronectin based scaffold proteins
|
WO2014126871A1
(en)
|
2013-02-12 |
2014-08-21 |
Bristol-Myers Squibb Company |
Tangential flow filtration based protein refolding methods
|
EP2956467B1
(en)
|
2013-02-12 |
2017-09-27 |
Bristol-Myers Squibb Company |
High ph protein refolding methods
|
PL2968461T3
(pl)
|
2013-03-13 |
2023-01-30 |
Genzyme Corporation |
Białka fuzyjne zawierające części wiążące pdgf i vegf oraz sposoby ich stosowania
|
US10653779B2
(en)
|
2013-03-13 |
2020-05-19 |
Genentech, Inc. |
Formulations with reduced oxidation
|
US20140314778A1
(en)
|
2013-03-13 |
2014-10-23 |
Genentech, Inc. |
Formulations with reduced oxidation
|
RU2707092C2
(ru)
|
2013-03-13 |
2019-11-22 |
Дженентек, Инк. |
Составы со сниженным окислением
|
NZ751452A
(en)
|
2013-03-13 |
2020-04-24 |
Genentech Inc |
Antibody formulations
|
US20160152686A1
(en)
|
2013-03-13 |
2016-06-02 |
Bristol-Myers Squibb Company |
Fibronectin based scaffold domains linked to serum albumin or moiety binding thereto
|
RU2707550C2
(ru)
|
2013-03-13 |
2019-11-27 |
Дженентек, Инк. |
Составы со сниженным окислением
|
PT3611180T
(pt)
|
2013-03-15 |
2022-03-15 |
Biomolecular Holdings Llc |
Imunoglobulina híbrida que contém uma ligação não peptídica
|
RU2718986C2
(ru)
|
2013-03-15 |
2020-04-15 |
Дженентек, Инк. |
Композиции клеточных культур с антиоксидантами и способы получения полипептидов
|
MX366112B
(es)
|
2013-03-15 |
2019-06-26 |
Genentech Inc |
Medio de cultivo celular y metodos de produccion de anticuerpos.
|
BR112015023140A8
(pt)
|
2013-03-15 |
2018-01-23 |
Genentech Inc |
proteínas de fusão, método para a fabricação da proteína de fusão, composições, ácido nucleico,vetor, célula hospedeira, métodos de produção de uma proteína de fusão, de tratamento da doença inflamatória intestinal, de inibição da infecção microbiana, de tratamento da lesão renal, para acelerar ou melhorar a cicatrização, para a prevenção ou tratamento de uma condição cardiovascular, para tratamento da síndrome metabólica e para tratamento da endotoxemia.
|
EP3626742A1
(en)
|
2013-09-27 |
2020-03-25 |
F. Hoffmann-La Roche AG |
Anti-pdl1 antibody formulations
|
US10203327B2
(en)
|
2013-11-05 |
2019-02-12 |
Novartis Ag |
Organic compounds
|
MX2016007965A
(es)
|
2013-12-17 |
2016-10-28 |
Genentech Inc |
Terapia de combinacion que comprende agonistas de union a ox40 y antagonistas de union al eje pd-1.
|
EP3083690A1
(en)
|
2013-12-17 |
2016-10-26 |
F.Hoffmann-La Roche Ag |
Methods of treating cancer using pd-1 axis binding antagonists and an anti-cd20 antibody
|
MY189089A
(en)
|
2013-12-17 |
2022-01-25 |
Genentech Inc |
Methods of treating cancers using pd-1 axis binding antagonists and taxanes
|
AU2015315834B2
(en)
|
2014-01-31 |
2019-12-12 |
Boehringer Ingelheim International Gmbh |
Novel anti-BAFF antibodies
|
EP3102197B1
(en)
|
2014-02-04 |
2018-08-29 |
Genentech, Inc. |
Mutant smoothened and methods of using the same
|
EP4169944A1
(en)
|
2014-03-14 |
2023-04-26 |
Biomolecular Holdings LLC |
Process for preparing hybrid immunoglobulin containing non-peptidyl linkage
|
ES2913840T3
(es)
|
2014-03-20 |
2022-06-06 |
Bristol Myers Squibb Co |
Dominios de tipo III de fibronectina de unión a seroalbúmina
|
ES2750563T3
(es)
|
2014-03-20 |
2020-03-26 |
Bristol Myers Squibb Co |
Moléculas con una estructura basada en fibronectina estabilizada
|
WO2015148736A1
(en)
|
2014-03-25 |
2015-10-01 |
Genentech, Inc. |
Methods of preparing a poloxamer for use in cell culture medium
|
MA39817A
(fr)
|
2014-03-31 |
2017-02-08 |
Hoffmann La Roche |
Thérapie combinatoires comprenant des agents anti-angiogenèse et des agonistes se liant à ox40
|
JP2017524359A
(ja)
|
2014-07-24 |
2017-08-31 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Il−23a関連疾患の処置に有用なバイオマーカー
|
CA2959545A1
(en)
|
2014-09-15 |
2016-03-24 |
Genentech, Inc. |
Antibody formulations
|
US20170211054A1
(en)
|
2014-09-30 |
2017-07-27 |
Dansico Us Inc. |
Compositions comprising beta mannanase and methods of use
|
EP3201331A1
(en)
|
2014-09-30 |
2017-08-09 |
Danisco US Inc. |
Compositions comprising beta mannanase and methods of use
|
EP3201334A1
(en)
|
2014-09-30 |
2017-08-09 |
Danisco US Inc. |
Compositions comprising beta-mannanase and methods of use
|
US20170226494A1
(en)
|
2014-09-30 |
2017-08-10 |
Danisco Us Inc. |
Compositions comprising beta-mannanase and methods of use
|
EP3201333A1
(en)
|
2014-09-30 |
2017-08-09 |
Danisco US Inc. |
Compositions comprising beta-mannanase and methods of use
|
WO2016059602A2
(en)
|
2014-10-16 |
2016-04-21 |
Glaxo Group Limited |
Methods of treating cancer and related compositions
|
KR20170096112A
(ko)
|
2014-11-17 |
2017-08-23 |
제넨테크, 인크. |
Ox40 결합 효능제 및 pd-1 축 결합 길항제를 포함하는 조합 요법
|
AU2015353573B2
(en)
|
2014-11-25 |
2020-09-03 |
Bristol-Myers Squibb Company |
Novel PD-L1 binding polypeptides for imaging
|
CN106413739B
(zh)
|
2014-12-09 |
2019-09-17 |
张文涛 |
Nbp158及其用途
|
US20170362621A1
(en)
|
2014-12-18 |
2017-12-21 |
Danisco Us Inc. |
Engineered multifunctional enzymes and methods of use
|
US20180002683A1
(en)
|
2014-12-18 |
2018-01-04 |
Danisco Us Inc. |
Engineered multifunctional enzymes and methods of use
|
JP6621478B2
(ja)
|
2014-12-19 |
2019-12-18 |
アルカーメス,インコーポレイテッド |
一本鎖Fc融合タンパク質
|
WO2016126638A1
(en)
|
2015-02-04 |
2016-08-11 |
Boehringer Ingelheim International Gmbh |
Methods of treating inflammatory diseases
|
WO2016126972A1
(en)
|
2015-02-04 |
2016-08-11 |
Genentech, Inc. |
Mutant smoothened and methods of using the same
|
CN107530425A
(zh)
|
2015-04-14 |
2018-01-02 |
勃林格殷格翰国际有限公司 |
治疗疾病的方法
|
CN107922474A
(zh)
|
2015-04-24 |
2018-04-17 |
Viiv保健英国第五有限公司 |
靶向hiv融合的多肽
|
WO2016196381A1
(en)
|
2015-05-29 |
2016-12-08 |
Genentech, Inc. |
Pd-l1 promoter methylation in cancer
|
MX2017016353A
(es)
|
2015-06-17 |
2018-05-02 |
Genentech Inc |
Metodos para tratar canceres de mama metastasicos o localmente avanzados con antagonistas de union al eje de pd-1 y taxanos.
|
TW202330904A
(zh)
|
2015-08-04 |
2023-08-01 |
美商再生元醫藥公司 |
補充牛磺酸之細胞培養基及用法
|
TWI811716B
(zh)
|
2015-09-18 |
2023-08-11 |
德商百靈佳殷格翰國際股份有限公司 |
治療發炎性疾病之方法
|
WO2017053617A1
(en)
|
2015-09-23 |
2017-03-30 |
Bristol-Myers Squibb Company |
Fast-off rate serum albumin binding fibronectin type iii domains
|
KR20180057657A
(ko)
|
2015-09-23 |
2018-05-30 |
브리스톨-마이어스 스큅 컴퍼니 |
글리피칸-3-결합 피브로넥틴 기반 스캐폴드 분자
|
JP7008023B2
(ja)
|
2015-12-30 |
2022-01-25 |
ジェネンテック, インコーポレイテッド |
低減されたポリソルベート分解を有する製剤
|
CN108430455A
(zh)
|
2015-12-30 |
2018-08-21 |
豪夫迈·罗氏有限公司 |
色氨酸衍生物用于蛋白质配制剂的用途
|
IL259588B2
(en)
|
2016-01-08 |
2023-09-01 |
Hoffmann La Roche |
Methods for the treatment of cea-positive cancer using pd-1 spindle-binding antagonists and bispecific antibodies against anti-cea and anti-cd3
|
TWI726969B
(zh)
|
2016-01-11 |
2021-05-11 |
比利時商健生藥品公司 |
用作雄性激素受體拮抗劑之經取代之硫尿囊素衍生物
|
CA3019952A1
(en)
|
2016-02-04 |
2017-08-10 |
Curis, Inc. |
Mutant smoothened and methods of using the same
|
US11767362B1
(en)
|
2016-03-15 |
2023-09-26 |
Chugai Seiyaku Kabushiki Kaisha |
Methods of treating cancers using PD-1 axis binding antagonists and anti-GPC3 antibodies
|
CA3018794A1
(en)
|
2016-04-15 |
2017-10-19 |
Boehringer Ingelheim International Gmbh |
Use of il-23 antibodies for treating generalized pustular psoriasis
|
US10994033B2
(en)
|
2016-06-01 |
2021-05-04 |
Bristol-Myers Squibb Company |
Imaging methods using 18F-radiolabeled biologics
|
KR102397783B1
(ko)
|
2016-06-01 |
2022-05-12 |
브리스톨-마이어스 스큅 컴퍼니 |
Pd-l1 결합 폴리펩티드에 의한 pet 영상화
|
UA126021C2
(uk)
|
2016-06-03 |
2022-08-03 |
Янссен Байотек, Інк. |
Домен фібронектину типу ііі, що зв'язується із сироватковим альбуміном
|
EP3497129A1
(en)
|
2016-08-08 |
2019-06-19 |
H. Hoffnabb-La Roche Ag |
Therapeutic and diagnostic methods for cancer
|
EP3526252A2
(en)
|
2016-10-14 |
2019-08-21 |
Boehringer Ingelheim International GmbH |
Methods of treating diseases with il-23a antibody
|
WO2018152496A1
(en)
|
2017-02-17 |
2018-08-23 |
The Usa, As Represented By The Secretary, Dept. Of Health And Human Services |
Compositions and methods for the diagnosis and treatment of zika virus infection
|
US20180273627A1
(en)
|
2017-03-27 |
2018-09-27 |
Boehringer Ingelheim International Gmbh |
Anti il-36r antibodies combination therapy
|
US11236151B2
(en)
|
2017-04-25 |
2022-02-01 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Antibodies and methods for the diagnosis and treatment of Epstein Barr virus infection
|
TW201842929A
(zh)
|
2017-05-03 |
2018-12-16 |
美商必治妥美雅史谷比公司 |
結合至肌肉生長抑制素以纖維連接蛋白為主之支架結構域蛋白質的穩定調配物
|
US10793634B2
(en)
|
2017-06-09 |
2020-10-06 |
Boehringer Ingelheim International Gmbh |
Anti-TrkB antibodies
|
US11827669B2
(en)
|
2017-07-19 |
2023-11-28 |
The Usa, As Represented By The Secretary, Dept. Of Health And Human Services |
Antibodies and methods for the diagnosis and treatment of hepatitis b virus infection
|
CN111479560A
(zh)
|
2017-10-16 |
2020-07-31 |
阿拉贡药品公司 |
用于治疗非转移性去势难治性***癌的抗雄激素
|
EP3728310A1
(en)
|
2017-12-18 |
2020-10-28 |
VIIV Healthcare UK (No.5) Limited |
Antigen binding polypeptides
|
WO2019148026A1
(en)
|
2018-01-26 |
2019-08-01 |
Genentech, Inc. |
Il-22 fc fusion proteins and methods of use
|
ES2932861T3
(es)
|
2018-01-26 |
2023-01-27 |
Hoffmann La Roche |
Composiciones de IL-22 Fc y procedimientos de uso
|
TW201946647A
(zh)
|
2018-02-21 |
2019-12-16 |
美商建南德克公司 |
利用il-22 fc融合蛋白進行治療之投藥
|
EP3788071A1
(en)
|
2018-05-02 |
2021-03-10 |
The United States Of America, As Represented By The Secretary, Department of Health and Human Services |
Antibodies and methods for the diagnosis, prevention, and treatment of epstein barr virus infection
|
US20200030443A1
(en)
|
2018-06-23 |
2020-01-30 |
Genentech, Inc. |
Methods of treating lung cancer with a pd-1 axis binding antagonist, a platinum agent, and a topoisomerase ii inhibitor
|
EP3813950A1
(en)
|
2018-06-29 |
2021-05-05 |
Boehringer Ingelheim International GmbH |
Anti-cd40 antibodies for use in treating autoimmune disease
|
CN112770775A
(zh)
|
2018-08-08 |
2021-05-07 |
豪夫迈·罗氏有限公司 |
色氨酸衍生物和l-蛋氨酸用于蛋白制剂的用途
|
ES2955032T3
(es)
|
2018-09-21 |
2023-11-28 |
Hoffmann La Roche |
Métodos de diagnóstico para el cáncer de mama triple negativo
|
EP3870614A1
(en)
|
2018-10-23 |
2021-09-01 |
GlyCardial Diagnostics, S.L. |
Antibodies specific for glycosylated apoj and uses thereof
|
EP3934617A1
(en)
|
2019-03-08 |
2022-01-12 |
Boehringer Ingelheim International GmbH |
Anti-il-36r antibody formulations
|
EP3966239A1
(en)
|
2019-05-09 |
2022-03-16 |
Boehringer Ingelheim International GmbH |
Anti-sema3a antibodies and their uses for treating eye or ocular diseases
|
TW202115112A
(zh)
|
2019-06-27 |
2021-04-16 |
德商百靈佳殷格翰國際股份有限公司 |
抗-angpt2抗體
|
TW202126685A
(zh)
|
2019-09-24 |
2021-07-16 |
德商百靈佳殷格翰國際股份有限公司 |
抗nrp1a抗體及其用於治療眼或眼部疾病之用途
|
CN111018960B
(zh)
*
|
2019-12-04 |
2021-09-10 |
中国农业科学院饲料研究所 |
一种抗菌肽id13及其制备方法和应用
|
CA3164996A1
(en)
|
2019-12-20 |
2021-06-14 |
Novarock Biotherapeutics, Ltd. |
Anti-interleukin-23 p19 antibodies and methods of use thereof
|
JP2023515633A
(ja)
|
2020-02-28 |
2023-04-13 |
ブリストル-マイヤーズ スクイブ カンパニー |
放射性標識されたフィブロネクチンに基づく足場および抗体ならびにそのセラノスティクス的使用
|
CA3176448A1
(en)
|
2020-03-31 |
2021-10-07 |
Repertoire Immune Medicines, Inc. |
Barcodable exchangeable peptide-mhc multimer libraries
|
WO2021207662A1
(en)
|
2020-04-10 |
2021-10-14 |
Genentech, Inc. |
Use of il-22fc for the treatment or prevention of pneumonia, acute respiratory distress syndrome, or cytokine release syndrome
|
BR112022023989A2
(pt)
|
2020-05-26 |
2023-02-07 |
Boehringer Ingelheim Int |
Anticorpos anti-pd-1
|
KR20230025691A
(ko)
|
2020-06-16 |
2023-02-22 |
제넨테크, 인크. |
삼중 음성 유방암을 치료하기 위한 방법과 조성물
|
US20230331867A1
(en)
|
2020-09-04 |
2023-10-19 |
Novarock Biotherapeutics, Ltd. |
Nectin-4 antibodies and uses thereof
|
WO2022087154A1
(en)
|
2020-10-20 |
2022-04-28 |
Repertoire Immune Medicines, Inc. |
Mhc class ii peptide multimers and uses thereof
|
WO2022162587A1
(en)
|
2021-01-27 |
2022-08-04 |
Centre Hospitalier Universitaire Vaudois (C.H.U.V.) |
Anti-sars-cov-2 antibodies and use thereof in the treatment of sars-cov-2 infection
|
WO2022170008A2
(en)
|
2021-02-05 |
2022-08-11 |
Boehringer Ingelheim International Gmbh |
Anti-il1rap antibodies
|
TW202317620A
(zh)
|
2021-06-04 |
2023-05-01 |
德商百靈佳殷格翰國際股份有限公司 |
抗SIRPα抗體
|
WO2022263638A1
(en)
|
2021-06-17 |
2022-12-22 |
Centre Hospitalier Universitaire Vaudois (C.H.U.V.) |
Anti-sars-cov-2 antibodies and use thereof in the treatment of sars-cov-2 infection
|
WO2023118312A1
(en)
|
2021-12-22 |
2023-06-29 |
Cdr-Life Ag |
Anti-c3 antibodies and antigen-binding fragments thereof and their uses for treating eye or ocular diseases
|
EP4238988A1
(en)
|
2022-03-01 |
2023-09-06 |
Consejo Superior De Investigaciones Científicas |
Antibodies against sars-cov-2 and uses thereof
|
WO2023196995A1
(en)
|
2022-04-07 |
2023-10-12 |
Repertoire Immune Medicines, Inc. |
T cell receptor multimers and uses thereof
|
WO2024068996A1
(en)
|
2022-09-30 |
2024-04-04 |
Centre Hospitalier Universitaire Vaudois (C.H.U.V.) |
Anti-sars-cov-2 antibodies and use thereof in the treatment of sars-cov-2 infection
|